4004 ESC Guidelines label use of medication should be limited to situations where it is in
the patient's interest to do so, with regard to the quality, safety, and efficacy of care, and only …

Health professionals are encouraged to take the Guidelines fully into account when
exercising their clinical judgment, as well as in the determination and the implementation of …

Pacemaker treatment for bradyarrhythmia was first approved for national health insurance
coverage in Japan in 1974, and its use rapidly became widespread thereafter …

This international multidisciplinary document intends to provide clinicians with evidence-
based practical patient-centered recommendations for evaluating patients and decedents …

Arrhythmogenic cardiomyopathy (ACM) is an arrhythmogenic disorder of the myocardium
not secondary to ischemic, hypertensive, or valvular heart disease. ACM incorporates a …

The recommendations listed in this clinical practice guideline are, whenever possible,
evidence-based. An initial extensive evidence review, which included literature derived from …

The recommendations listed in this guideline are, whenever possible, evidence based. An
initial extensive evidence review, which included literature derived from research involving …

The present document has been conceived as the European update to the American
College of Cardiology (ACC)/American Heart Association (AHA)/ESC 2006 Guidelines for …

Background Recurrent ventricular tachycardia among survivors of myocardial infarction with
an implantable cardioverter–defibrillator (ICD) is frequent despite antiarrhythmic drug …

Ventricular arrhythmias are an important cause of morbidity and mortality and come in a
variety of forms, from single premature ventricular complexes to sustained ventricular …